The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Letter to the editor

Are we compromising on value versus performance: time to consider the Portico valve as a third major market player?

EuroIntervention 2019;15:e818-e819. DOI: 10.4244/EIJ-D-18-00966L

1. Division of Cardiac Surgery, Department of Surgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 2. Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA


We found the recent study by Maisano et al very thought-provoking, given the focus on the commercial experience using the Portico™ bioprosthetic valve (Abbott, Santa Clara, CA, USA) in the multicentre PORTICO-1 study1. We applaud the authors for conducting this important study which further adds to a growing body of evidence demonstrating the overall safety (low mortality) and acceptable clinical and haemodynamic outcomes (low transvalvular gradients and low rate of moderate-high paravalvular leak) of the Portico valve2,3,4.

While innovation in transcatheter aortic valve replacement (TAVR) devices and adoption of the procedure have occurred rapidly, it appears that ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Reply to the letter to the editor “Are we compromising on value versus performance: time to consider the Portico valve as a third major market player?”. Rapid implementation of new therapies, new devices, new procedures... fast but under control: be vigilant!

Latest news